Today, TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, announced that Eric Smith has been named Chief Commercial Officer, effective August 31, 2018.
In this newly created role, which will report directly to the Chief Executive Officer, Mr. Smith will lead the company’s global commercialization efforts, with a focus on both strategic and tactical execution efforts in sales, upstream and downstream marketing, field clinical support and training with a focus on adoption and clinical excellence.
“We are very excited to have Eric join the TransEnterix team. He brings a wealth of experience commercializing innovative technologies on a global scale,” said Todd M. Pope, Chief Executive Officer of TransEnterix. “As we look to drive widespread adoption of Senhance, we believe that the addition of Eric’s expertise in developing and driving sales and marketing strategies will complement our existing team as we continue to grow and increase our presence in the United States and around the world.”
Mr. Smith brings over two decades of medical technology experience to TransEnterix, with over a decade of that focused on commercial leadership and marketing strategy. Most recently, he was a Vice President, Franchise Leader Acute Care at KCI Corporation, a developer and manufacturer of wound healing products. While at KCI, he was responsible for the development and commercialization of innovative wound-care technologies on a global scale. Prior to joining KCI, Mr. Smith served as Vice President of Global Strategic Marketing at Cordis Corporation, a developer and manufacturer of medical devices for the treatment of coronary and peripheral vascular diseases. He has also held senior positions at Boston Scientific, C.R. Bard and Ernst & Young. He received his Bachelor’s degree from the University of New Hampshire and his MBA from Babson College.
“I am extremely pleased to be joining TransEnterix during such an exciting time in the company’s history,” said Smith. “Senhance is a transformative technology with a large market opportunity, and I look forward to contributing to the company’s success and improving clinical outcomes and patient care through the use of digital laparoscopy.”